CUE-101 is a fusion protein commercialized by Cue Biopharma, with a leading Phase I program in Oropharyngeal Cancer. According to Globaldata, it is involved in 5 clinical trials, of which 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of CUE-101’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for CUE-101 is expected to reach an annual total of $36 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CUE-101 Overview

CUE-101 is under development for the treatment of human papillomavirus (HPV) associated cancers (head and neck cancer squamous cell carcinoma, recurrent head and neck cancer squamous cell carcinoma, anal cancer, oropharyngeal squamous-cell carcinoma (OPSCC) and cervical cancer). The drug candidate is administered by parenteral route. Drug candidate consist of IL-2 and a pMHC composed of HLA-A 02:01 complexed with a dominant peptide derived from the human papilloma virus E7 protein (HPV-E7). CUE-101 is developed using Immuno-STAT technology. It was also under development for the treatment of non-small cell lung cancer. It is acts by targeting HPV-E7 (human papilloma virus- E7 oncoprotein) interleukin 2 receptor.

Cue Biopharma Overview

Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse. CUE-200 series to give a boost to exhausted T cells and CUE-300 series. It offers therapy in areas of immuno onncology, infectious diseases and autoimmune diseases. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, is designed to regulate the body’s intrinsic immune system. The company also provides clinical trails and research services. Cue Biopharma is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$14.9 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$3.2 million in FY2020. The operating loss of the company was US$43.7 million in FY2021, compared to an operating loss of US$45 million in FY2020. The net loss of the company was US$44.2 million in FY2021, compared to a net loss of US$44.8 million in FY2020.

For a complete picture of CUE-101’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.